Estimated Prevalence Of Cryptococcus Antigenemia (Crag) Among Hiv-Infected Adults With Advanced Immunosuppression In Namibia Justifies Routine Screening And Preemptive Treatment

BackgroundCryptococcal meningitis is common and associated with high mortality among HIV infected persons. The World Health Organization recommends that routine Cryptococcal antigen (CrAg) screening in ART-naive adults with a CD4(+) count <100 cells/mu L followed by preemptive antifungal therapy for CrAg-positive patients be considered where CrAg prevalence is >= 3%. The prevalence of CrAg among HIV adults in Namibia is unknown. We estimated CrAg prevalence among HIV-infected adults receiving care in Namibia for the purpose of informing routine screening strategies.MethodsThe study design was cross-sectional. De-identified plasma specimens collected for routine CD4(+) testing from HIV-infected adults enrolled in HIV care at 181 public health facilities from November 2013 to January 2014 were identified at the national reference laboratory. Remnant plasma from specimens with CD4(+) counts <200 cells/mu L were sampled and tested for CrAg using the IMMY (R) Lateral Flow Assay. CrAg prevalence was estimated and assessed for associations with age, sex, and CD4(+) count.ResultsA total of 825 specimens were tested for CrAg. The median (IQR) age of patients from whom specimens were collected was 38 (32-46) years, 45.9% were female and 62.9% of the specimens had CD4 <100 cells/mu L. CrAg prevalence was 3.3% overall and 3.9% and 2.3% among samples with CD4(+) counts of CD4(+)<100 cells/mu L and 100-200 cells/mu L, respectively. CrAg positivity was significantly higher among patients with CD4+ cells/mu L < 50 (7.2%, P = 0.001) relative to those with CD4 cells/mu L 50-200 (2.2%).ConclusionThis is the first study to estimate CrAg prevalence among HIV-infected patients in Namibia. CrAg prevalence of >= 3.0% among patients with CD4(+)<100 cells/mu L justifies routine CrAg screening and preemptive treatment among HIV-infected in Namibia in line with WHO recommendations. Patients with CD4(+)<100 cells/mu L have a significantly greater risk for CrAg positivity. Revised guidelines for ART in Namibia now recommend routine screening for CrAg.